Pharma Pioneer

Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab

19 May 2024
2 min read

Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, known as SPOTLIGHT, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab. The study involves administering a single dose of the drug subcutaneously at two varying levels to adult patients with cold urticaria or symptomatic dermographism. The company, which is also conducting the BEACON study for chronic spontaneous urticaria (CSU), anticipates preliminary results in the latter half of 2024. The SPOTLIGHT trial aims to enroll around 15 patients and is taking place at four European Union sites. The study's primary focus is on the safety and tolerability of briquilimab, with secondary goals to assess its efficacy and pharmacokinetics.

Briquilimab is an aglycosylated monoclonal antibody that targets the c-Kit receptor, which is involved in mast cell-driven diseases such as chronic urticaria. The drug has shown efficacy and safety in over 145 participants and is also being studied for lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell therapies for rare diseases.

Jasper Therapeutics is a clinical-stage company developing briquilimab for the treatment of chronic mast and stem cell diseases and as a conditioning agent for stem cell transplants. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Celularity Seeks FDA Orphan Drug Status for PDA-002 to Treat FSHD
Pharma Pioneer
2 min read
Celularity Seeks FDA Orphan Drug Status for PDA-002 to Treat FSHD
19 May 2024
Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.
Read →
23andMe Launches Phase 1 Trial for ULBP6-Targeted Dual-Action Antibody 23ME-01473
Pharma Pioneer
2 min read
23andMe Launches Phase 1 Trial for ULBP6-Targeted Dual-Action Antibody 23ME-01473
19 May 2024
A clinical trial has been initiated for an innovative drug candidate, 23ME-01473, developed by 23andMe Holding Co., a prominent entity in human genetics and biopharmaceuticals.
Read →
ACELYRIN Reports Positive Early-Stage Results for Lonigutamab in Treating Thyroid Eye Disease
Pharma Pioneer
3 min read
ACELYRIN Reports Positive Early-Stage Results for Lonigutamab in Treating Thyroid Eye Disease
19 May 2024
Significant advancements have been observed in the treatment of thyroid eye disease (TED) with lonigutamab, a humanized monoclonal antibody.
Read →
Inhalon Biopharma's Inhaled Antibody Platform Outperforms IV in Safety and Efficacy Study
Pharma Pioneer
2 min read
Inhalon Biopharma's Inhaled Antibody Platform Outperforms IV in Safety and Efficacy Study
19 May 2024
Inhalon Biopharma, a company in the clinical stage, has revealed initial findings from a pivotal Phase 1b clinical trial.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.